Navigation Links
Vion Reports 2007 Third Quarter and Nine-Month Results
Date:11/7/2007

ical trials sponsored by the National Cancer Institute. For additional information on Vion and its product development programs, visit the Company's Internet web site at http://www.vionpharm.com.

This news release contains forward-looking statements. Such statements are subject to certain risk factors which may cause Vion's plans to differ or results to vary from those expected, including Vion's potential inability to obtain regulatory approval for its products, delayed or unfavorable results of drug trials, the possibility that favorable results of earlier preclinical studies or clinical trials are not predictive of safety and efficacy results in later clinical trials, the need for additional research and testing, the potential inability to secure external sources of funding to continue operations, the inability to access capital and funding on favorable terms, continued operating losses and the inability to continue operations as a result, and a variety of other risks set forth from time to time in Vion's filings with the Securities and Exchange Commission, including but not limited to the risks attendant to the forward-looking statements included under Item 1A, "Risk Factors" in Vion's Form 10-K for the year ended December 31, 2006 and the Company's Form 10-Q for the quarter ended June 30, 2007. In particular, there can be no assurance as to the results of any of the Company's clinical trials, that any of these trials will continue to full accrual, or that any of these trials will not be discontinued, modified, delayed or ceased altogether. Except in special circumstances in which a duty to update arises under law when prior disclosure becomes materially misleading in light of subsequent events, Vion does not intend to update any of these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

COMPANY CONTACT: Vion Ph
'/>"/>

SOURCE Vion Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. New Study Reports High Injury Rates for Hotel Workers, Even Higher Rates for Women and Nonwhites
2. Haemacure Reports Third Quarter 2007 Results
3. First-Ever List of the 5,000 Fastest-Growing Businesses Reports Total Revenue of $194.5 Billion
4. Consumer Reports Analysis: Drugs for Nerve Pain, Fibromyalgia Effective, But Not Always Best
5. MDS Reports Third Quarter 2007 Results
6. Allied Healthcare Reports Strong Fourth Quarter, Flat Net Income for Fiscal 2007 vs. 2006
7. AtriCure Reports First Human Implant of the Cosgrove-Gillinov Left Atrial Appendage Occlusion System
8. NMHC Reports Fourth Quarter and Fiscal Year 2007 Financial Results
9. Blue Cross and Blue Shield of Florida Reports Eighteenth Consecutive Year of Positive Performance
10. ReBuilder Medical Technologies, Inc. Reports International Sales Expansion
11. AdCare Health Systems, Inc. Reports Discontinuation of Definitive Merger Agreement with Family Home Health Services, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2015)... ... , ... On Tuesday, July 28th, Symantec released a security industry whitepaper ... the attack on Anthem Inc. which resulted in one of the largest data breaches ... spear phishing campaigns. , For Joe Caruso, founder and CEO/CTO of ...
(Date:7/31/2015)... ... July 31, 2015 , ... That’s right, the STASH ... STASH awards? The Significant Technological Achievements in Secretive Horticulture (or STASH) Awards, featured ... tried-and-true products that have stood the test of time. These include lighting products, ...
(Date:7/31/2015)... ... July 31, 2015 , ... Ticket Down is a ... going on in Chicago at Grant Park. The festival will end on Sunday, ... America to Chicago for the annual Lollapalooza. This unique and unbelievably popular festival ...
(Date:7/31/2015)... ... ... Sculpted Contours Luxury Medical Aesthetics announces the arrival of the newest applicator for ... applicator in the United States as an upgrade to the CoolSmooth applicator cleared by ... required a 2 hour treatment time. The new CoolSmooth Pro reduces the treatment ...
(Date:7/31/2015)... ... , ... M3 USA MDLinx.com, source of the Smartest Doc Board Exam Prep ... , The additions of Gastroenterology, Pulmonology and Allergy/Immunology round out an already robust selection ... exam easy and painless. MDLinx offers thousands of board-exam style questions and exam-specific ...
Breaking Medicine News(10 mins):Health News:Frenemy at the Gates - Hackers Excel at Leveraging Trust 2Health News:Frenemy at the Gates - Hackers Excel at Leveraging Trust 3Health News:Frenemy at the Gates - Hackers Excel at Leveraging Trust 4Health News:The High Times S.T.A.S.H. Awards Are in, Guess Who Took Home the Prize for “Best Grow System” 2Health News:Cheap 2015 Lollapalooza Tickets: Ticket Down Slashes Ticket Prices on Lollapalooza Tickets at Grant Park in Chicago for Saturday, August 1st and Sunday, August 2nd 2Health News:Cooler Coolsculpting in Atlanta: Treatments Now Twice As Fast 2Health News:Cooler Coolsculpting in Atlanta: Treatments Now Twice As Fast 3Health News:MDLinx Offers Three New Board Exam Prep Courses - Gastroenterology, Pulmonology and Allergy/Immunology 2Health News:MDLinx Offers Three New Board Exam Prep Courses - Gastroenterology, Pulmonology and Allergy/Immunology 3
... , , , MINNEAPOLIS, ... and marketer of state-of-the-art cardiac surgery products and services, today reported financial ... (Logo: http://www.newscom.com/cgi-bin/prnh/20040202/ATSILOGO ) , , Second ... or 17.0% higher than the second quarter of 2008. Revenue from ...
... CRANBURY, N.J., Aug. 3 Innophos Holdings, Inc. (Nasdaq: ... financial results for the second quarter 2009. , , ... Net sales for the second quarter 2009 were $166.8 million, ... the same period in 2008. Selling price increases had a positive effect ...
... , , SAN DIEGO, Aug. ... financial results for the second quarter ended June 30, 2009. , ... in the second quarter of 2009 of $38.0 million, or $0.48 per share, ... of 2008 of $65.8 million, or $0.89 per share, and a net loss ...
... , , BIRMINGHAM, Ala., Aug. 3 ... reports Operating Income of $50.4 million, or $1.52 per diluted share for ... million, or $1.62 per diluted share. For the six months ended June ... and Net Income was $82.2 million, or $2.46 per diluted share. , ...
... NEW YORK, Aug. 3 The uninsured issue has become a ... are currently without health insurance, a number that is continuing to ... large hospitals and clinics for sick visits and emergencies -- as ... patients arrive at hospitals and clinics, by State law, the facility ...
... a good time with friends, researchers say, , MONDAY, Aug. ... why one in 10 high school seniors have tried opioid ... reasons included relaxation, feeling good or getting high, experimentation and ... hydrocodone, oxycodone, hydromorphone, meperidine, morphine and codeine without a prescription, ...
Cached Medicine News:Health News:ATS Medical Announces Second Quarter 2009 Results 2Health News:ATS Medical Announces Second Quarter 2009 Results 3Health News:ATS Medical Announces Second Quarter 2009 Results 4Health News:ATS Medical Announces Second Quarter 2009 Results 5Health News:ATS Medical Announces Second Quarter 2009 Results 6Health News:ATS Medical Announces Second Quarter 2009 Results 7Health News:ATS Medical Announces Second Quarter 2009 Results 8Health News:ATS Medical Announces Second Quarter 2009 Results 9Health News:ATS Medical Announces Second Quarter 2009 Results 10Health News:ATS Medical Announces Second Quarter 2009 Results 11Health News:Innophos Holdings, Inc. Reports Second Quarter 2009 Results 2Health News:Innophos Holdings, Inc. Reports Second Quarter 2009 Results 3Health News:Innophos Holdings, Inc. Reports Second Quarter 2009 Results 4Health News:Innophos Holdings, Inc. Reports Second Quarter 2009 Results 5Health News:Innophos Holdings, Inc. Reports Second Quarter 2009 Results 6Health News:Innophos Holdings, Inc. Reports Second Quarter 2009 Results 7Health News:Innophos Holdings, Inc. Reports Second Quarter 2009 Results 8Health News:Innophos Holdings, Inc. Reports Second Quarter 2009 Results 9Health News:Innophos Holdings, Inc. Reports Second Quarter 2009 Results 10Health News:Innophos Holdings, Inc. Reports Second Quarter 2009 Results 11Health News:Innophos Holdings, Inc. Reports Second Quarter 2009 Results 12Health News:Innophos Holdings, Inc. Reports Second Quarter 2009 Results 13Health News:Innophos Holdings, Inc. Reports Second Quarter 2009 Results 14Health News:Innophos Holdings, Inc. Reports Second Quarter 2009 Results 15Health News:Arena Pharmaceuticals Announces Second Quarter 2009 Financial Results and Recent Developments 2Health News:Arena Pharmaceuticals Announces Second Quarter 2009 Financial Results and Recent Developments 3Health News:Arena Pharmaceuticals Announces Second Quarter 2009 Financial Results and Recent Developments 4Health News:Arena Pharmaceuticals Announces Second Quarter 2009 Financial Results and Recent Developments 5Health News:Arena Pharmaceuticals Announces Second Quarter 2009 Financial Results and Recent Developments 6Health News:Arena Pharmaceuticals Announces Second Quarter 2009 Financial Results and Recent Developments 7Health News:Arena Pharmaceuticals Announces Second Quarter 2009 Financial Results and Recent Developments 8Health News:Arena Pharmaceuticals Announces Second Quarter 2009 Financial Results and Recent Developments 9Health News:Arena Pharmaceuticals Announces Second Quarter 2009 Financial Results and Recent Developments 10Health News:ProAssurance Reports Second Quarter 2009 Results 2Health News:ProAssurance Reports Second Quarter 2009 Results 3
(Date:7/30/2015)... PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced ... second quarter ending June 30, 2015. ... We are excited to be near the completion of ... with topline results expected in the fourth quarter," stated ... Inc. "Translarna is now commercially available in 12 countries ...
(Date:7/30/2015)... 30, 2015 Eisai Inc. announced today that ... United States , European Union and ... respectively) for eribulin, for the treatment of patients with ... chemotherapy for advanced or metastatic disease. ... pivotal global Phase 3 clinical trial (Study 309), which ...
(Date:7/30/2015)... 30, 2015  Medimetriks Pharmaceuticals, Inc. announced today ... III clinical study for Ozenoxacin, a novel bactericidal ... the exclusive U.S. rights to Ozenoxacin 1% cream.  ... 44 centers with an emphasis on U.S. patients, ... months and older with a clinical diagnosis of ...
Breaking Medicine Technology:PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 2PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 3PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 4PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 5PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 6PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 7PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 8PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 9PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 10Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 2Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 3Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 4Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 5Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 2Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 3
... June 11, 2007 /PRNewswire/ -- GlaxoSmithKline,plc announced ... of its investigational non-peptide oral platelet growth,factor, ... that PROMACTA at 50-75mg once daily resulted ... and also,reduced bleeding in adult patients with ...
... Phase 1 Clinical Trial of SNS-595 in Acute,Leukemia ... June 11, 2007,/PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. presented,positive ... company's,anti-cancer product candidates, SNS-595 and SNS-032, at the ... Vienna,Austria. , Interim Results from Sunesis' Phase 1 ...
Cached Medicine Technology:Pivotal Phase III Trial Showed Promacta (eltrombopag olamine),Raised Platelet Counts and Reduced Bleeding in Patients With,Chronic ITP 2Pivotal Phase III Trial Showed Promacta (eltrombopag olamine),Raised Platelet Counts and Reduced Bleeding in Patients With,Chronic ITP 3Pivotal Phase III Trial Showed Promacta (eltrombopag olamine),Raised Platelet Counts and Reduced Bleeding in Patients With,Chronic ITP 4Pivotal Phase III Trial Showed Promacta (eltrombopag olamine),Raised Platelet Counts and Reduced Bleeding in Patients With,Chronic ITP 5Pivotal Phase III Trial Showed Promacta (eltrombopag olamine),Raised Platelet Counts and Reduced Bleeding in Patients With,Chronic ITP 6Sunesis Pharmaceuticals Reports Positive Data From Studies of Two,Anti-Cancer Agents, SNS-595 and SNS-032, at the 12th Congress of,the European Hematology Association 2Sunesis Pharmaceuticals Reports Positive Data From Studies of Two,Anti-Cancer Agents, SNS-595 and SNS-032, at the 12th Congress of,the European Hematology Association 3Sunesis Pharmaceuticals Reports Positive Data From Studies of Two,Anti-Cancer Agents, SNS-595 and SNS-032, at the 12th Congress of,the European Hematology Association 4Sunesis Pharmaceuticals Reports Positive Data From Studies of Two,Anti-Cancer Agents, SNS-595 and SNS-032, at the 12th Congress of,the European Hematology Association 5Sunesis Pharmaceuticals Reports Positive Data From Studies of Two,Anti-Cancer Agents, SNS-595 and SNS-032, at the 12th Congress of,the European Hematology Association 6
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: